Free Trial

Summit Therapeutics (SMMT) Competitors

Summit Therapeutics logo
$21.20 -0.08 (-0.38%)
Closing price 07/1/2025 04:00 PM Eastern
Extended Trading
$21.36 +0.16 (+0.78%)
As of 08:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SMMT vs. TAK, ARGX, ONC, BNTX, TEVA, ITCI, GMAB, RDY, ASND, and VTRS

Should you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

Summit Therapeutics vs. Its Competitors

Takeda Pharmaceutical (NYSE:TAK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Summit Therapeutics has a consensus target price of $34.67, suggesting a potential upside of 63.52%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Takeda Pharmaceutical
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Summit Therapeutics
2 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.79

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Takeda Pharmaceutical has a net margin of 2.36% compared to Summit Therapeutics' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 10.64% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Takeda Pharmaceutical2.36% 10.64% 5.14%
Summit Therapeutics N/A -62.87%-51.61%

In the previous week, Summit Therapeutics had 11 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 14 mentions for Summit Therapeutics and 3 mentions for Takeda Pharmaceutical. Summit Therapeutics' average media sentiment score of 0.75 beat Takeda Pharmaceutical's score of 0.59 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Takeda Pharmaceutical
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Summit Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Takeda Pharmaceutical has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.02, suggesting that its stock price is 202% less volatile than the S&P 500.

Takeda Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.09B1.63$712.33M$0.2269.91
Summit Therapeutics$700K22,492.29-$221.32M-$0.34-62.35

Summary

Takeda Pharmaceutical beats Summit Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Summit Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SMMT vs. The Competition

MetricSummit TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$15.80B$2.43B$5.48B$8.94B
Dividend YieldN/A1.79%5.38%4.12%
P/E Ratio-62.358.7826.2119.74
Price / Sales22,492.29636.32395.51109.12
Price / CashN/A154.3736.4957.06
Price / Book40.004.467.915.37
Net Income-$221.32M$31.16M$3.15B$248.34M
7 Day Performance-0.33%0.38%0.77%1.67%
1 Month Performance19.57%8.14%3.46%4.56%
1 Year Performance181.17%3.02%34.61%18.42%

Summit Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMMT
Summit Therapeutics
2.6319 of 5 stars
$21.20
-0.4%
$34.67
+63.5%
+160.4%$15.80B$700K-62.35110Analyst Upgrade
TAK
Takeda Pharmaceutical
1.229 of 5 stars
$14.72
-0.3%
N/A+18.4%$46.84B$4.58T66.9149,281
ARGX
argenex
4.3104 of 5 stars
$540.76
-0.3%
$709.18
+31.1%
+24.9%$33.02B$2.25B33.361,599Trending News
Analyst Forecast
ONC
BeOne Medicines
3.4891 of 5 stars
$257.51
+4.2%
$319.00
+23.9%
N/A$28.22B$3.81B-69.2211,000Gap Up
BNTX
BioNTech
2.4665 of 5 stars
$103.01
-3.3%
$137.86
+33.8%
+36.4%$24.76B$2.98B-30.306,772Gap Down
TEVA
Teva Pharmaceutical Industries
4.0507 of 5 stars
$16.96
+0.1%
$24.44
+44.1%
+2.0%$19.45B$16.54B-14.7536,830
ITCI
Intra-Cellular Therapies
0.9104 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.8921 of 5 stars
$20.68
-2.3%
$39.17
+89.4%
-16.5%$13.26B$3.12B11.752,682High Trading Volume
RDY
Dr. Reddy's Laboratories
3.0164 of 5 stars
$15.31
+0.5%
$16.95
+10.7%
-1.0%$12.78B$3.81B23.2027,811Positive News
ASND
Ascendis Pharma A/S
3.5208 of 5 stars
$175.78
-0.6%
$220.67
+25.5%
+28.4%$10.75B$393.54M-27.991,017
VTRS
Viatris
3.0314 of 5 stars
$8.85
-0.2%
$10.40
+17.5%
-13.3%$10.39B$14.74B-2.7932,000

Related Companies and Tools


This page (NASDAQ:SMMT) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners